Wegovy weight loss results in the first month: the honest picture

You've just started Wegovy and the number hasn't moved much, is that normal?

Picture this: you're at the end of week four, you step on the scale, and you've lost about 1.5 kg. You were expecting more. Here's the context that matters. The 0.25 mg starting dose exists specifically to reduce nausea; its job is to let your digestive system settle in, not to produce dramatic weight loss. Almost everyone begins here, regardless of their starting weight. A prescriber will typically increase the dose to 0.5 mg after four weeks, and the appetite-suppressing effect strengthens meaningfully with each step up the titration ladder.

That said, one kilogram of fat requires a deficit of roughly 7,700 kcal. If Wegovy has reduced your daily intake by around 300–500 kcal (a realistic early effect) a two-kilogram loss in four weeks is genuinely good progress, even if it feels modest. Some people lose more. A few lose very little in month one and then find the losses accelerate once the dose increases, and if you want to understand what that first month typically looks like in practice, the Wegovy 1 month results page sets out what the evidence and real-world experience actually show. The timeline for Wegovy taking full effect is measured in months, not weeks.

One practical habit worth building in week one: photograph your starting weight on your phone alongside today's date. When month three arrives and you've lost eight kilograms, you'll want that reference point. Memory is unreliable; photos aren't.

What early results actually show in the clinical evidence

The STEP 1 trial recruited 1,961 adults with obesity or overweight plus a weight-related condition, over 68 weeks at 2.4 mg semaglutide. Average weight loss across the full study was around 15% of body weight, as reported in the NEJM STEP 1 paper. Month-one data from large trials is rarely published in isolation because the titration phase is not the treatment phase, the first four weeks are essentially a run-in period.

What we do know from published subgroup analyses and clinical practice is that meaningful appetite suppression tends to kick in around weeks two to four for most people, but the scale lags the biology. Water retention fluctuates, and early GI symptoms (if you experience them) can mask fat loss with short-term fluid shifts. Reviewing longer-term Wegovy results data puts month one in proper proportion: it is the foundation, not the finished building.

The newer 7.2 mg dose (approved by the MHRA in January 2026 and now available as a single-dose pen) recorded an average weight loss of around 20.7% over 72 weeks in trials, narrowing the gap with tirzepatide at higher doses. That headline figure is a long-run number, and it starts with the same 0.25 mg first month that every patient goes through.

Side effects in the first four weeks and what to do about them

Nausea is the most commonly reported early experience, and it is worth being ready for it rather than surprised by it. The NHS semaglutide patient page lists nausea, vomiting, diarrhoea, constipation, indigestion and headache as common effects, with most being mild to moderate. Eating smaller portions, avoiding rich or fatty meals, and staying well hydrated all help. These effects are most pronounced after your first injection and often again after each dose increase.

Pancreatitis is a rarer but serious concern: severe stomach pain that radiates to the back, with or without vomiting, requires urgent medical attention and you should stop taking the medicine until you have been assessed. The MHRA highlighted this in a Drug Safety Update for GLP-1 medicines in January 2026. Any suspected side effects can be reported at the MHRA's Yellow Card scheme.

One thing that often surprises people: early side effects are not a sign the medicine is harming you. They are a sign the GLP-1 pathway is active. They usually settle within two to three weeks. If they don't, or if they're severe, contact your prescriber, not a forum. For a fuller view of what month two tends to look like once the 0.5 mg dose is established, the two-month results page covers that shift in detail.

How individual factors shape your month-one number

Starting weight matters enormously. Someone who begins at 120 kg losing 2 kg has moved 1.7% of their body weight; someone starting at 85 kg losing the same 2 kg has moved 2.4%. The medicine's licensed indication covers adults with a BMI of 30 or above, or 27 and above with a weight-related condition such as high blood pressure or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. But BMI alone doesn't determine how the first month goes.

Diet and activity in month one also shape the outcome. Wegovy reduces appetite; it doesn't replace the need to eat adequately, stay hydrated, or move. Protein intake matters particularly, people who maintain protein while eating less tend to preserve muscle better. If you're weighing up treatment options more broadly, the weight loss overview covers how different licensed medicines compare in principle. If you're already decided and want to understand the cost side of things, Wegovy pricing in the UK gives a factual breakdown of what private treatment involves.

The range of month-one outcomes is genuinely wide: from almost no scale change to five or six kilograms for a small number of people. Neither extreme tells you much about where you'll be at six months. The six-month results picture is where the clinical evidence becomes most clinically meaningful.